International Bladder Cancer Update Archives

Overview – Bladder Cancer Clinical Trials Where We Stand At The End Of 2024

Posted by Daniel P. Petrylak, MD | Feb 2025

Daniel P. Petrylak, MD, analyzes bladder cancer treatment advancements, emphasizing recent clinical practice breakthroughs and challenges.

High-Risk/BCG Naïve: Treatment of Choice

Posted by Michael A. O'Donnell, MD, FACS | Feb 2025

Michael A. O’Donnell, MD, discusses BCG’s role as the standard treatment for non-muscle invasive bladder cancer (NMIBC).

Bladder Cancer Biomarkers: Surveillance

Posted by Yair Lotan, MD | Feb 2025

Yair Lotan, MD, discusses urinary biomarkers and highlights their evolving role in bladder cancer detection and surveillance.

Intermediate-Risk NMIBC/BCG Naïve: Treatment of Choice

Posted by Leonard G. Gomella, MD, FACS | Feb 2025

Leonard G. Gomella, MD, FACS, explores bladder cancer treatment, particularly in the context of intermediate-risk, BCG-naïve disease.

International Bladder Cancer Update Expert Forum

Posted by Susan Hill | Nov 2023

International Bladder Cancer Update Expert Forum Grand Hyatt • Washington, DC December 1-3, 2023 Agenda Faculty Support Opportunities The diagnosis, management, and treatment of patients with bladder cancer is rapidly evolving...